You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Version: 1 avr 2023
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
Sarah Salama, Leta Forbes, Daniela Gallo-Hershberg

Guideline Objective

To provide clinicians with guidance on implementation of routine, pre-treatment DPYD testing and genotype-guided dosing for cancer patients with planned fluoropyrimidine treatment in Ontario.

Patient Population

Cancer patients who are candidates for systemic treatment with fluoropyrimidines (5-fluorouracil or capecitabine)

Intended Guideline Users

Health care providers involved in the care of cancer patients who have planned systemic treatment with fluoropyrimidines (medical oncologists, nurses, pharmacists)

pdf download Summary (PDF) (275.63 Ko)
pdf download Full Report (PDF) (453.18 Ko)

Guideline-Based Clinical Tools

Summary of Pre-treatment Dosing Recommendations (for providers)
Testing for people taking capecitabine or 5-fluorouracil (5-FU) (for patients)
Dépistage chez les personnes prenant de la capécitabine ou du 5-fluorouracile (5-FU)